相关实验视频

Updated: Jun 14, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

莫苏涅图祖马布加Pola-CHP与Pola-R-CHP相比,在以前未经治疗的DLBCL中:第二阶段研究的最终结果

Jason Westin¹, Tycel J Phillips², Amitkumar Mehta³

¹Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

|February 5, 2025

概括

这项研究比较了mosunetuzumab加Pola-M-CHP与Pola-R-CHP用于扩散大B细胞淋巴瘤. 两种治疗都显示出类似的完全响应率,但Pola-R-CHP的严重不良事件较少.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
目前的一线治疗包括化学免疫治疗方案.
正在研究新的组合来改善结果.

研究的目的:

为了评估mosunetuzumab加循环胺,多克索鲁比辛,普雷尼松和波拉图祖马布维多丁 (Pola-M-CHP) 与波拉图祖马布维多丁-瑞图西马布加循环胺,多克索鲁比辛和普雷尼松 (Pola-R-CHP) 作为DLBCL的第一线治疗的疗效和安全性.

主要方法:

一项2期随机性研究招募了62名DLBCL患者.
患者接受了6个周期的Pola-M-CHP或Pola-R-CHP.
莫苏尼图祖马布与Pola-M-CHP通过分级剂量和30毫克剂量一起使用.

主要成果:

完全响应 (CR) 率相似:Pola-M-CHP的72.5%与Pola-R-CHP的77.3%相比.
在Pola-M-CHP的24个月无进展生存率为70.8%,Pola-R-CHP为81.8%.
与Pola-M-CHP相比,Pola-M-CHP的3级以上不良事件 (86.8%),严重不良事件 (63.2%) 和治疗中止 (13.2%) 的比率更高.

结论:

在这个第二阶段的研究中,添加Pola-CHP的莫苏尼图祖马布没有显示出对Pola-R-CHP的临床益处.
在活性时,Pola-M-CHP组合与更高的毒性概况有关.
进一步的调查可能是合理的,但Pola-R-CHP在本试验中显示出潜在的更好的安全性.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...